Literature DB >> 10912522

Effect of chronic renal failure and growth hormone therapy on the insulin-like growth factors and their binding proteins.

D R Powell1, F Liu, B K Baker, R L Hinzt, A Kale, A Suwanichkul, S K Durham.   

Abstract

Children with chronic-renal failure (CRF) are often growth retarded, and abnormalities of the growth hormone (GH)/insulin-like growth factor (IGF) axis in CRF may contribute to this poor growth. Despite normal IGF levels in CRF serum, IGF bioactivity is low due to excess IGF-binding proteins (IGFBPs) in the 35-kDa serum fractions. Levels of IGFBP-1, -2, -4 and -6, and a 29-kDa IGFBP-3 fragment, are high in CRF serum, and levels of intact IGFBP- 1 and -2 correlate negatively with height. IGFBP-1 levels may be high due to insulin resistance, suggesting that the FKHR family of transcription factors may play a role in the overexpression of IGFBP-1, and other growth inhibitors, in CRF. GH-treated CRF children show catch-up growth that correlates positively with a rise in each component of the 150-kDa serum ternary complex (IGF-I or -II/IGFBP-3 or -5/acid-labile subunit); IGFBP-1, -2 and -6 levels do not rise, but serum IGF bioactivity does. Thus, GH increases levels of IGFs and ternary complexes in CRF serum. It is likely that increased IGFs contribute to catch-up growth by overcoming the inhibitory effects of excess IGFBPs present in the CRF milieu.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912522     DOI: 10.1007/s004670000349

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  11 in total

1.  Recombinant human growth hormone therapy in autosomal recessive polycystic kidney disease.

Authors:  Marusia Lilova; Bernard S Kaplan; Kevin E C Meyers
Journal:  Pediatr Nephrol       Date:  2002-11-26       Impact factor: 3.714

Review 2.  Nutrition and growth in children with chronic kidney disease.

Authors:  Lesley Rees; Robert H Mak
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

3.  Role of Growth Hormone Deficiency and Treatment in Chronic Kidney Disease.

Authors:  Diptesh Gupta; Michael Gardner; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-07-26       Impact factor: 2.041

Review 4.  Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling.

Authors:  Ralph Rabkin; Di Fei Sun; Yu Chen; Jane Tan; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

5.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

Review 6.  The growth hormone-insulin-like growth factor-I axis in chronic kidney disease.

Authors:  Robert H Mak; Wai W Cheung; Charles T Roberts
Journal:  Growth Horm IGF Res       Date:  2007-09-07       Impact factor: 2.372

Review 7.  Current advances in chronic kidney disease in children: growth, cardiovascular, and neurocognitive risk factors.

Authors:  Larry A Greenbaum; Bradley A Warady; Susan L Furth
Journal:  Semin Nephrol       Date:  2009-07       Impact factor: 5.299

8.  IGF-binding protein-3 fragments in plasma of a child with acute renal failure.

Authors:  Victoria Schebek-Fürstenberg; Ludger Ständker; Martin Oppermann; Dirk E Müller-Wiefel; Wilfried Hahn; Werner F Blum; Thomas Braulke; Bernd Kübler
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

9.  Insulin-like growth factor binding protein-2 modulates podocyte mitogenesis.

Authors:  Darren J Bridgewater; Douglas G Matsell
Journal:  Pediatr Nephrol       Date:  2003-08-29       Impact factor: 3.714

Review 10.  Growth retardation in children with kidney disease.

Authors:  Paulina Salas; Viola Pinto; Josefina Rodriguez; Maria Jose Zambrano; Veronica Mericq
Journal:  Int J Endocrinol       Date:  2013-09-25       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.